Tabelecleucel for EBV-related lymphoma after transplant treatment failure
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a solid organ transplant (kidney, liver, heart, lungs, pancreas, small bowel) or an allogeneic bone marrow/stem cell transplant
- Your biopsy-confirmed PTLD is linked to EBV (EBV positive)
- Your scans show measurable body disease that lights up on PET (Deauville score 3 or higher), unless a scan type is required by your clinic
- Your PTLD did not respond or has progressed after rituximab (or a similar biosimilar) and/or rituximab plus chemotherapy
- Your blood counts and organs are strong enough for treatment (specific minimum levels for white cells, platelets, liver tests)
- You can give consent and meet age/activity needs (good enough daily functioning for your age)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This early-phase trial tests lab-made “memory” immune T cells that target Epstein-Barr virus (EBV). It may help people whose EBV infection has caused lymphomas or serious complications after a transplant.
This trial tests a new drug called epcoritamab for people whose PTLD (a type of lymphoma that can happen after an organ transplant) has come back or hasn't been helped by standard treatments. The goal is to see if epcoritamab can shrink or control the cancer.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This study tests whether a medication called rituximab can help prevent a type of cancer (PTLD) that sometimes develops in transplant patients whose body is fighting a reactivated virus (EBV). You may qualify if you've had an organ transplant, have high levels of EBV in your blood, and haven't yet developed this cancer.
This study tests whether a single dose of rituximab (a targeted antibody therapy) given after a donor stem cell transplant can reduce dangerous levels of the EBV virus in the blood. It aims to prevent a serious complication called PTLD (lymphoma-like disease) that sometimes occurs after transplant.
Hear when a new Solid Organ Transplant Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.